RNTX · Rein Therapeutics, Inc. · Metrics
Market Cap
$64.56M
Shares
86.27M
Volume · Oct 5
336.3K
Avg daily vol (3M)
425.02K
RNTX metrics
50 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$0.80
Market cap
$64.56M
Price action
20 metricsPrice change (1W)
+7.0%
Price change (30D)
-7.2%
Price change (3M)
-19.3%
Price change (6M)
-33.8%
Price change (YTD)
-31.0%
Price change (1Y)
-31.0%
Trailing year
Price change (5Y)
—
52-week high
$1.88
52-week low
$0.70
Change from 52-week high
-57.4%
Change from 52-week low
+14.0%
Annualized volatility
87.5%
Annualized volatility (3M)
71.8%
Beta
1.8
RSI (14D)
51.4
Price vs SMA 50
+1.9%
Price vs SMA 200
-26.8%
Avg volume (3M)
425,019
Relative volume
1.1
Average dollar volume
$345,230
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
86.27M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.2
reciprocal yield 85.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-77.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$49.46M
Net income (TTM)
−$49.76M
Trailing 12 months
Diluted EPS (TTM)
$-1.72
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+177.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-90.1%
Return on assets
-75.4%
Debt / equity
—
Current ratio
4.3
EBITDA (TTM)
−$49.46M
Free cash flow (TTM)
—
Quick ratio
4.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$40.65M
Latest balance sheet
Cash & equivalents
$8.54M
Total assets
$65.97M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$18.83M
Capital expenditures (TTM)
$157,000
R&D (TTM)
$10.39M
SG&A (TTM)
—
Stock compensation (TTM)
$2.02M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
59
13F filer change QoQ
+13
Institutional ownership
47.2%
Short interest
3 metricsShort interest
0.8%
Latest settlement · 1.4 days to cover
Days to cover
1.4d
Short-squeeze score
43 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—